Mitotane for adrenocortical carcinoma treatment

Area of Science:

• Endocrinology
• Oncology
• Pharmacology

Background:

• Adrenocortical carcinoma (ACC) is a rare cancer with a poor prognosis.
• Mitotane is the sole adrenal-specific treatment for ACC, but its properties and mechanism are not fully understood.
• Metabolic activation is crucial for mitotane's adrenolytic effect.

Purpose of the Study:

• To review the pharmacological properties of mitotane.
• To analyze the efficacy of mitotane in treating adrenocortical carcinoma.
• To discuss challenges and future directions in mitotane therapy for ACC.

Main Methods:

• Review of published clinical reports and retrospective analyses of mitotane use in ACC.
• Analysis of mitotane's pharmacological properties and mechanism of action.
• Evaluation of mitotane's efficacy, including objective tumor regression and hormone excess control.

Main Results:

• Mitotane demonstrates activity against ACC, with objective tumor regression in approximately 25% of cases.
• Mitotane effectively controls hormone excess in the majority of treated patients.
• Frequent side effects, primarily gastrointestinal and central nervous system, are associated with mitotane treatment.

Conclusions:

• Mitotane is an effective agent for adrenocortical carcinoma, offering tumor regression and hormone control.
• Identifying patient subsets who benefit from mitotane is crucial to optimize treatment and avoid toxicity.
• Further elucidation of mitotane's pharmacology and mechanism is needed for improved therapeutic strategies.